{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-120902","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.093652+00:00","generated_at":"2026-05-30T06:36:17.123744+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Heron Therapeutics appoints Michael Kaseta to Board of Directors","bullets":["Michael Kaseta, CFO/COO of Liquidia, appointed to Heron's Board effective Nov. 4, 2024.","Kaseta brings biopharma finance and commercial expertise; served as CFO at Aerami and Aralez.","Previously CFO of Sanofi North America, managing a $10B business across 100+ products.","Will receive standard non-employee director compensation and enter indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-120902","json":"https://secwatch.observer/filing/0000950170-24-120902.json","markdown":"https://secwatch.observer/filing/0000950170-24-120902.md","text":"https://secwatch.observer/filing/0000950170-24-120902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017024120902/0000950170-24-120902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017024120902/hrtx-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:36:17.123744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4d32a81bb","claim":"Michael Kaseta was appointed as Director at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"On November 4, 2024, the Board of Directors (the \"Board\") of Heron Therapeutics, Inc. (the \"Company\") appointed Michael Kaseta to the Board to serve for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017024120902/0000950170-24-120902-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}